
|Videos|November 9, 2017
Improved Understanding of JAK2 Inhibition in Polycythemia Vera
Author(s)John O. Mascarenhas, MD
John O. Mascarenhas, MD, associate professor of medicine, Icahn School of Medicine at Mount Sinai Hospital, discusses the optimal use of ruxolitinib (Jakafi) and the improved understanding of JAK2 inhibition of polycythemia vera.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
The Targeted Pulse: FDA Decisions and Clinical Advancements
2
FDA Accepts NDA for 177Lu-edotreotide in GEP-NETs
3
Long-Term Follow-Up Confirms Benefits of Low-Dose Seminoma Treatment
4
FDA Authorizes EXENT System to Aid Myeloma Diagnosis
5







































